Home › Funds › ADAR1 Capital Management, LLC › VIR
ADAR1 Capital Management, LLC position in VIR
VIR BIOTECHNOLOGY INC · Health Care
ADAR1 Capital Management, LLC reported holding 2,456,677 shares of VIR (VIR BIOTECHNOLOGY INC) in its Q2 2026 13F filing — a position valued at US$25.0M, representing 1.39% of its reported portfolio and ranking #14 among its reported holdings. ADAR1 Capital Management, LLC has disclosed VIR holdings in 7 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's VIR position evolved
ADAR1 Capital Management, LLC first disclosed a stake in VIR in Q2 2024 at 110,000 shares (US$979K). The position peaked in Q2 2026 at 2,456,677 shares, worth US$25.0M. Across 7 filings, ADAR1 Capital Management, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 2,456,677 shares valued at US$25.0M — a reduction of -288,037 shares quarter over quarter.. Notable position changes include a 190% increase in Q3 2024 (shares fell 2% over the following quarter), a 80% trim in Q4 2024 (shares fell 12% over the following quarter), a 290% increase in Q1 2025 (shares fell 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 110.00K | $979.00K | New |
| Q3 2024 | 319.19K | $2.39M | Add |
| Q4 2024 | 64.07K | $470.25K | Reduce |
| Q1 2025 | 250.00K | $1.62M | Add |
| Q2 2025 | 250.00K | $1.26M | Hold |
| Q1 2026 | 2.74M | $24.59M | New |
| Q2 2026 | 2.46M | $25.03M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VIR and 13F data
VIR (VIR BIOTECHNOLOGY INC) is a Health Care company. 49 other funds we track also report a position in VIR — the largest reported positions include ARCH Venture Management, LLC (US$129.4M), SB INVESTMENT ADVISERS (UK) LTD (US$111.6M), GSK plc (US$87.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VIR
- ARCH Venture Management, LLC 12.69M sh · $129.35M · Q2 2026
- SB INVESTMENT ADVISERS (UK) LTD 10.95M sh · $111.56M · Q2 2026
- GSK plc 8.55M sh · $87.13M · Q2 2026
- Boxer Capital Management, LLC 1.87M sh · $19.01M · Q2 2026
- GordonMD Global Investments LP 1.35M sh · $13.79M · Q2 2026
- Sio Capital Management, LLC 1.08M sh · $10.96M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 853.68K sh · $8.70M · Q2 2026
- Saturn V Capital Management LP 770.64K sh · $7.85M · Q2 2026
- Jones Hill Capital LP 659.21K sh · $6.72M · Q2 2026
- Avidity Partners Management LP 519.30K sh · $5.29M · Q2 2026
- Alta Partners Management Company, L.P. 509.92K sh · $5.20M · Q2 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held VIR?
ADAR1 Capital Management, LLC has disclosed VIR holdings in 7 of the last 9 reported quarters, going back to Q2 2024.
What is ADAR1 Capital Management, LLC's current position in VIR?
As of Q2 2026, ADAR1 Capital Management, LLC holds 2.46M shares of VIR (VIR BIOTECHNOLOGY INC), valued at $25.03M, representing 1.39% of its reported portfolio and ranking #14.
Has ADAR1 Capital Management, LLC been buying or selling VIR?
In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC reduced its position in VIR. The position peaked in Q2 2026 at 2.46M shares.
Which other funds hold VIR?
Other major institutional holders of VIR include ARCH Venture Management, LLC, SB INVESTMENT ADVISERS (UK) LTD, GSK plc, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.